HACKENSACK, N.J., Dec. 14 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. announced today that Scott Myers has been appointed as Senior Vice President, Strategic Marketing & Commercialization. He will be responsible for attracting potential development and commercialization partners and establishing the Company's business intelligence and strategic marketing units.
Mr. Myers brings 15 years' experience in market analysis and product launch activities. Mr. Myers held senior management roles in Johnson & Johnson for the last five years. Most recently, he was General Manager of McNeil Specialty Pharmaceuticals, where he had overall P&L responsibility, managed the Concerta(R) and Flexeril(R) brands and was accountable for more than 800 full-time employees. Directly prior to McNeil, Mr. Myers was Senior Vice President at Ortho Biotech Products, L.P., responsible for new business, new product development, strategic services and sales operations. Before joining Ortho Biotech, he served as Senior Vice President and Chief Information Officer of Johnson & Johnson Pharmaceutical Research & Development, where he reported directly to the Chairman and oversaw a global staff of 200 and systems operations in the United States, Europe and Asia.
"We are delighted that Scott has joined the DOV team and will be bringing to our endeavors his considerable experience in pharmaceutical commercialization" said Dr. Leslie Hudson, President and CEO of DOV. "To most effectively position bicifadine as the analgesic of choice in the pain market, we will continue with our strategy and commitment to enhancing our commercial development capabilities. Scott's skill set is an enormous asset in this regard to us and we welcome him to DOV."
Earlier in his career, Mr. Myers co-founded ISO Health Care Group, a global strategy consultancy. He also has held positions at Baxter Healthcare and Andersen Consulting. Mr. Myers earned his B.A in biology from Northwestern University and an M.B.A. in finance and international business from the University of Chicago.
About DOV
DOV is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of novel drug candidates for central nervous system and other disorders, including cardiovascular, which involve alterations in neuronal processing. Our product candidates address some of the largest pharmaceutical markets in the world including insomnia, pain and depression. Our partner Neurocrine has filed two NDAs for the use of DOV's compound indiplon for the treatment of insomnia.
Cautionary Note
Statements in this press release that are not historical facts constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act, each as amended, including statements regarding our expectations with respect to the progress of and level of expenses for our clinical trial programs. You can also identify forward-looking statements by the following words: may, will, should, expect, intend, plan, anticipate, believe, estimate, predict, potential, continue or the negative of these terms or other comparable terminology. We caution you that forward-looking statements are inherently uncertain and are simply point-in-time estimates based on a combination of facts and factors currently known by us about which we cannot be certain. Actual results or events will surely differ and may differ materially from our forward-looking statements as a result of many factors, some of which we may not be able to predict or may not be within our control. Such factors may also materially adversely affect our ability to achieve our objectives and to successfully develop and commercialize our product candidates, including our ability to:
-- Demonstrate the safety and efficacy of product candidates at each stage of development; -- Meet our development schedule for our product candidates, including with respect to clinical trial initiation, enrollment and completion; -- Develop an acceptable development plan under and otherwise achieve the results contemplated by the recent amendment to the existing license agreement with Merck; -- Meet applicable regulatory standards and receive required regulatory approvals on our anticipated time schedule or at all; -- Meet obligations and required milestones under our license and other agreements; -- Obtain and maintain collaborations as required with pharmaceutical partners; -- Obtain substantial additional funds; -- Obtain and maintain all necessary patents or licenses; and -- Produce drug candidates in commercial quantities at reasonable costs and compete successfully against other products and companies.
Factors that may cause our actual results to differ materially from our forward-looking statements include (i) one or more of our product candidates could be shown to cause harmful side effects, (ii) one or more of our product candidates may not exhibit the expected therapeutic results, (iii) we or the FDA may place on clinical hold one or more of our clinical trials, and neither we nor the agency may determine to lift such hold, (iv) patient recruitment may be slower than expected or patients may drop out of our clinical trials, (v) regulatory approval for our product candidates may not be received or may be delayed, (vi) our licensees and collaborative partners on whom our success depends may not fulfill their obligations to us and (vii) required financings may be delayed or deferred owing to market conditions. You should also refer to the risks discussed in our other filings with the Securities and Exchange Commission including those contained in our annual report on Form 10-K filed on March 15, 2005, and Form 10-Q filed on November 9, 2005. We qualify all our forward-looking statements by these cautionary statements. There may be other factors that may materially affect our forward-looking statements and our future results. Readers should not, therefore, place undue reliance on our forward-looking statements. We do not undertake any obligation and do not intend to update any forward-looking statement.
DOV Pharmaceutical, Inc.CONTACT: Alan Beckhard, Manager, Investor Relations and CorporateCommunications, DOV Pharmaceutical, Inc., +1-201-968-0980
Web site: http://www.dovpharm.com/
